Member Content

Small Rare Disease Biotech Screens Attractive

by Joe Kunkle | Jan 3, 2025

Eton Pharma (ETON) caught my eye with morning news of an acquisition of Galzin, a FDA-approved as a maintenance treatment of patients with Wilson Disease who have been initially treated with a chelating agent.
ETON further caught by eye with the char...

Please login to continue reading this article.

Options Hawk Max

$399 | 30 days

Options Hawk Trading Hub Live Chat
Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
Live Mock Portfolio
1 on 1 Access
Hawk’s Trader Toolbox
Street Research
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
Weekly and Monthly OpEx Sheets
Notable Options Database
OptionsHawk Quarterly Market Brief

More About this Plan

Options Hawk Elite

$199 | 30 days

Hawk’s Market Blitz
Spotlight Trades (2 Per Week)
Market Recap
Weekly Earnings Snapshots
OptionsHawk Research
Daily Options Radar
OptionHawk’s Weekly Radar Report
Options Hawk Market Outlook Access
Daily Earnings Grid
OptionsHawk Quarterly Market Brief

More About this Plan